Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2026 ,inter alia, to consider and approve unaudited (Standalone and Consolidated) Financial Statements of the Company for the second quarter ended 30th September 2026

To To Date: November 03, 2026 Listing Compliance Department BSE Limited National Stock Exchange of India Limited, 1st Floor, New Trading Ring, Exchange Plaza, 5th Floor, Plot No. C/2, G Rotunda Building, P.J. Block, Towers, Bandra Kurla Complex, Bandra (E), Dalal Street, Mumbai-400051 Mumbai – 400001 Symbol: BALPHARMA Scrip Code: 524824 Sub: Prior Intimation of Board Meeting pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, Pursuant to Regulation 29 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of Bal Pharma Limited is scheduled to be held on Wednesday, November 11, 2026, inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026 (Q2/2026-27) and such other matters as may be considered necessary with the permission of the Chair. Please takes this intimation on your records Thanking You. For Bal Pharma Limited Shreepada ML Company Secretary and Compliance officer ICSI M No: A66681